Pfizer (PFE), Astellas Pharma Inc. Reports Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer

December 20, 2018 9:06 AM
Pfizer Inc. (NYSE: PFE), Astellas Pharma Inc. today announced that the Phase 3 ARCHES trial evaluating XTANDI® (enzalutamide) plus androgen ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Hot FDA News Management Comments

Next Articles